An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer (CRPC), known for its limited treatment options. The research, led by investigators at Memorial Sloan-Kettering Cancer Center, appears early online and in an upcoming edition of The Lancet.
Shorter Radiation Course Stops Cancer Growth in High-risk Prostate Cancer Patients
Hypofractionated radiation treatment, a newer type of radiation treatment that delivers higher doses of radiation in fewer treatments than conventional radiation therapy, is significantly more effective than the older method in stopping cancer growth in high risk patients and causes no increase in negative side effects, an Italian clinical trial shows.
Short Course High-Dose Radiation (IMRT) Looks Safe and Effective for Higher-Risk Prostate Cancer
ASTRO – A shorter, 5-week course of radiation treatment that delivers higher doses of radiation in fewer sessions, known as hypofractionation, appears just as effective and as safe for moderate and higher risk prostate cancer as standard radiation therapy, yet is delivered in two-and-a-half weeks less time.
Shorter and Safer Hospital Stays But More Risk of Incontinence and Erectile Dysfunction, Study Shows
New research indicates that the use of minimally invasive procedures (including the use of robotic assistance) for radical prostatectomy, which have increased significantly in recent years, may shorten hospital stays and decrease respiratory and surgical complications, but may also result in an increased rate of certain complications, including incontinence and erectile dysfunction, according to a study in the October 14 issue of JAMA
NSAID Made No Difference to Cancer Growth
To see whether Celebrex (celecoxib) can reduce prostate cancer size and spread, a team from several leading US cancer centers led by Dr. Alan Partin and Dr. Michael Carducci conducted a randomized, double-blind trial enrolling high-risk men before primary treatment with surgery or radiation. They measured the effect of celecoxib on drug-specific biomarkers from prostate tissue obtained at prostatectomy on these men.
Dr. Gerald Chodak outlines controversy over antiandrogens
Men fighting metastatic prostate cancer may be frustrated to discover that doctors disagree with one another. For example, a lot of controversy surrounds the question of whether to block male hormones from the adrenal gland by use of a drug such as bicalutamide (Casodex). In a video, Dr. Gerald Chodak, a Chicago urologist, discusses how to maximize survival.
Since prostate cancer screening increased, more older men are surviving the disease through Active Surveillance, aka “Watchful Waiting”
Older men who were diagnosed with prostate cancer after early 1990 and were treated with conservative management (“Watchful Waiting”) lived significantly longer than men in similar situation 10 or 20 years previous to that.
This is the finding of a large new study based on Medicare patients’ records. The study is published in September 15 issue of the Journal of the American Medical Association (JAMA) by a team at The Cancer Institute of New Jersey (CINJ).
Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to a study in the August 26 issue of JAMA.
Prostate cancer patients who undergo therapy to decrease testosterone levels increase their risk of developing bone- and heart-related side effects compared to patients who do not take these medications, according to a new analysis. A new review of the data suggests that the absolute increases in these risks are fairly low, but proper care is essential to minimize them.
For Low Risk Prostate Cancer, Personalized Monitoring An Option
Active surveillance may be a viable option for some men with prostate cancer. Regular tests and careful tracking of any changes in the patient’s disease risk over time are imperative to ensure good outcomes, according to researchers in Toronto presenting at the annual meeting of the American Urological Association (AUA).